Bottom line
FSPHX vs FACDX: the short answer
FSPHX (Health Care Portfolio) and FACDX (Fidelity Advisor Health Care Fund) share a meaningful slice of their top holdings — about 76% by weight.
FSPHX is cheaper at 0.62% vs 0.96% — a difference of $34 a year per $10,000 invested.
Over five years, FSPHX returned +4.0% a year vs +2.3% for FACDX (reporting dates differ).
Updated Nov 19, 2026
FSPHX vs FACDX side by side
| FSPHX | FACDX | |
|---|---|---|
| Type | Mutual fund | Mutual fund |
| Fund family | Fidelity | Fidelity |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.62% | 0.96% |
| Annual cost per $10k | $62 | $96 |
| 10-yr cost on $10k (prospectus) | $774 | $1,685 |
| Max front load | — | — |
| 12b-1 fee | 0% | 0.25% |
| 1-yr return | +14.4% | +7.7% |
| 5-yr return (annualized) | +4.0% | +2.3% |
| 10-yr return (annualized) | +9.0% | +7.6% |
| Best quarter | +22.2% | +21.3% |
| Worst quarter | −15.0% | −15.0% |
| Net assets (fund) | $5.8B | $3.1B |
| Number of holdings | 152 | 154 |
| Portfolio turnover | 69% | 74% |
| Returns as of | Apr 30, 2026 | Sep 30, 2026 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | FSPHX | FACDX | Difference |
|---|---|---|---|
| 2025 | +14.4% | +14.2% | +0.2% |
| 2024 | +4.9% | +3.9% | +1.0% |
| 2023 | +4.1% | +3.8% | +0.3% |
| 2022 | −12.8% | −13.1% | +0.3% |
| 2021 | +11.5% | +11.2% | +0.3% |
| 2020 | +24.4% | +21.1% | +3.4% |
| 2019 | +31.5% | +27.9% | +3.6% |
| 2018 | +7.4% | +7.3% | +0.1% |
| 2017 | +24.0% | +24.1% | −0.1% |
| 2016 | −10.7% | −10.3% | −0.4% |
Source: Fund prospectus bar charts
Holdings overlap
19 of FSPHX's top 25 holdings also appear in FACDX's top 25.
| Holding | FSPHX | FACDX |
|---|---|---|
| ELI LILLY and CO | 8.03% | 7.66% |
| Danaher Corp | 6.89% | 6.75% |
| JOHNSON and JOHNSON | 4.91% | 3.78% |
| Thermo Fisher Scientific Inc | 4.33% | 6.31% |
| Unitedhealth Group Inc | 3.49% | 4.17% |
| Alnylam Pharmaceuticals Inc | 2.40% | 1.78% |
| Gilead Sciences Inc | 2.21% | 1.25% |
| Boston Scientific Corp | 2.17% | 1.23% |
| Ascendis Pharma A/s | 2.17% | 1.95% |
| Fidelity Revere Street Trust | 2.17% | 2.54% |
| Abbvie Inc | 2.03% | 3.62% |
| Ucb Sa | 2.03% | 1.32% |
| MERCK and CO INC | 1.60% | 2.09% |
| Argenx Se | 1.56% | 2.09% |
| Cvs Health Corp | 1.29% | 1.29% |
Source: SEC Form N-PORT
FSPHX top 10
- ELI LILLY and CO — 8.03%
- Danaher Corp — 6.89%
- JOHNSON and JOHNSON — 4.91%
- Thermo Fisher Scientific Inc — 4.33%
- Unitedhealth Group Inc — 3.49%
- Alnylam Pharmaceuticals Inc — 2.40%
- Gilead Sciences Inc — 2.21%
- Boston Scientific Corp — 2.17%
- Ascendis Pharma A/s — 2.17%
- Fidelity Revere Street Trust — 2.17%
FACDX top 10
- ELI LILLY and CO — 7.66%
- Danaher Corp — 6.75%
- Thermo Fisher Scientific Inc — 6.31%
- Unitedhealth Group Inc — 4.17%
- JOHNSON and JOHNSON — 3.78%
- Abbvie Inc — 3.62%
- Fidelity Revere Street Trust — 2.54%
- Argenx Se — 2.09%
- MERCK and CO INC — 2.09%
- West Pharmaceutical Svcs Inc — 2.06%
FAQ
What is the difference between FSPHX and FACDX?
Which is cheaper, FSPHX or FACDX?
Should I own both FSPHX and FACDX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.